<DOC>
	<DOCNO>NCT00003018</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Chemotherapy follow surgery may effective treatment pancreatic cancer . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient stage II stage III pancreatic cancer surgically remove .</brief_summary>
	<brief_title>S9700 Combination Chemotherapy Treating Patients With Stage II Stage III Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess one year overall survival rate patient advance , unresectable pancreatic cancer treat fluorouracil , leucovorin , mitomycin dipyridamole . II . Assess response rate group patient . III . Evaluate frequency severity toxic effect associate therapy . IV . Assess rate resectability patient respond therapy . OUTLINE : All patient undergo surgical placement indwell central venous line . Patients receive fluorouracil IV continuous infusion day 1-28 , leucovorin calcium IV day 1 , 8 , 15 , 22 , oral dipyridamole day 1-28 , mitomycin IV every 6 week start day 1 . Treatment repeat every 6 week 4 course . Patients partial complete response reevaluate possible surgical resection . Resected patient resume chemotherapy 4-8 week surgery additional 16 week . Patients follow every 6 month 2 year , annually death . PROJECTED ACCRUAL : A total 55 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven stage II III pancreatic adenocarcinoma Ductal adenocarcinoma Mucinous noncystic carcinoma Signet ring cell carcinoma Adenosquamous carcinoma Undifferentiated ( anaplastic ) carcinoma Mixed ductalendocrine carcinoma Well differentiate adenocarcinoma Moderately well poorly differentiate adenocarcinoma Undifferentiated ductal carcinoma Must unresectable localized disease Measurable evaluable disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception Loss great 15 % actual body weight Oral intake great 1,200 calorie per day No malignancy within past 5 year except adequately treat basal squamous cell skin cancer , carcinoma situ cervix , stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy pancreatic cancer Endocrine therapy : Not specify Radiotherapy : No prior radiation therapy pancreatic cancer Surgery : At least 2 week since prior surgical bypass procedure recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>duct cell adenocarcinoma pancreas</keyword>
</DOC>